The US Food and Drug Administration FDA approved the kinase inhibitor LENVIMA lenvatinib for the first-line treatment of patients with unresectable hepatocellular carcinoma HCC This approval was based on results from REFLECT where LENVIMA demonstrated a p [...]
While studying a large group of individuals with chronic lymphocytic leukemia CLL a Wilmot Cancer Institute scientific team made an important discovery these patients had a sizable 600 percent higher risk of melanoma the most dangerous form of skin cance [...]
The US Food and Drug Administration FDA today approved Azedra iobenguane I 131 for the treatment of pheochromocytoma or paraganglioma which are rare neuroendocrine tumors of the adrenal gland and other tissue areas About Pheochromocytoma and Paraganglioma [...]
Currently it is recommended that most postmenopausal women with hormone receptorpositive early stage breast cancer be treated with 5 additional years of aromatase inhibitor AI therapy following completion of an initial 5 years of treatment The optimal dur [...]
Tibsovo ivosidenib has been granted approval from the US Food and Drug Administration FDA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia RR AML with a susceptible isocitrate dehydrogenase-1 IDH1 mutation as detected [...]
The US Food and Drug Administration today approved Kisqali ribociclib in combination with an aromatase inhibitor for the treatment of preperimenopausal or postmenopausal women with hormone receptor HR-positive human epidermal growth factor receptor 2 HER2 [...]
Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck SCCHN About Head and Neck Cancer Head and neck cancers include a nu [...]
On July 13 2018 the Food and Drug Administration approved Xtandi enzalutamide for patients with castration-resistant prostate cancer CRPC This approval broadens the indicated patient population to include patients with both non-metastatic CRPC NM-CRPC and [...]
Andrew X Zhu MD PhD director of Liver Cancer Research at Massachusetts General Hospital presented new data at the 2018 World Congress on Gastrointestinal Cancer WCGC demonstrating that Cyramza ramucirumab significantly improves survival in a subset of pat [...]
Two clinical studies highlight the importance of evaluating overall health instead of age in the management of lung cancer In fact younger patients with non-small cell lung cancer NSCLC are more likely to receive treatment than older patients regardless o [...]
